Q-omics provides the consensus-scored MIR548AM profile across patient tissues and cancer cell-line models. MIR548AM expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, MIR548AM is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, MIR548AM RNA expression shows 9,991 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight LUSC, BRCA, and DLBC as cancer lineages where MIR548AM shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR548AM — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR548AM survival associations across molecular data types. MIR548AM RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR548AM RNA expression–survival associations across cancer types. High MIR548AM expression shows unfavorable associations in LIHC, DLBC and PAAD, but favorable associations in LUSC, GBM and OV. The LUSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .010). Together, the overview and detailed table identify LUSC as the clearest survival context for MIR548AM RNA expression.
This table summarizes MIR548AM tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR548AM. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR548AM shows higher tumor expression in BRCA, CHOL, PRAD, KIRC and LUSC. The BRCA box plot shows higher MIR548AM RNA expression in tumor versus normal tissue (log2 FC = +0.805, t-test p < 0.001).
This table shows molecular features associated with MIR548AM in patient tissues and cancer cell lines. In patient samples, MIR548AM shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
